Morgan Stanley Maintains Overweight on CME Group, Lowers Price Target to $353

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

Morgan Stanley analyst Michael Cyprys maintains CME Group (NASDAQ:CME) with a Overweight and lowers the price target from $362 to $353.